Access the full text.
Sign up today, get DeepDyve free for 14 days.
Harry Bear, S. Anderson, A. Brown, Roy Smith, E. Mamounas, B. Fisher, R. Margolese, Heather Theoret, A. Soran, D. Wickerham, N. Wolmark (2003)
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 22
M. Rimawi, I. Mayer, A. Forero, R. Nanda, M. Goetz, Angel Rodriguez, A. Pavlick, Tao Wang, S. Hilsenbeck, C. Gutierrez, R. Schiff, C. Osborne, Jenny Chang (2013)
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 14
L. Gianni, G. Bianchini, A. Kiermaier, G. Bianchi, Y. Im, T. Pieńkowski, L. Roman, M. Liu, L. Tseng, J. Ratnayake, T. Szado, G. Ross, P. Valagussa (2011)
S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC).Cancer Research, 71
D. Slamon, W. Eiermann, N. Robert, T. Pieńkowski, Miguel Martín, M. Press, J. Mackey, J. Glaspy, A. Chan, M. Pawlicki, T. Pintér, V. Valero, Mei-Ching Liu, G. Sauter, G. Minckwitz, F. Visco, V. Bée, M. Buyse, B. Bendahmane, I. Tabah-Fisch, M. Lindsay, A. Riva, J. Crown (2011)
Adjuvant trastuzumab in HER2-positive breast cancer.The New England journal of medicine, 365 14
J. Baselga, I. Bradbury, H. Eidtmann, S. Cosimo, E. Azambuja, C. Aura, H. Gómez, P. Dinh, K. Fauria, V. Dooren, G. Aktan, A. Goldhirsch, Tsai-Wang Chang, Z. Horváth, M. Coccia-Portugal, J. Dômont, L. Tseng, G. Kunz, J. Sohn, V. Semiglazov, G. Lerzo, M. Pálácova, V. Probachai, L. Pusztai, M. Untch, R. Gelber, M. Piccart-Gebhart (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialThe Lancet, 379
E. Perez, J. Eckel-Passow, K. Ballman, S. Anderson, E. Thompson, Y. Asmann, J. Jen, A. Dueck, W. Lingle, G. Sledge, E. Winer, J. Gralow, R. Jenkins, M. Reinholz (2012)
Abstract PD10-04: Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant studyCancer Research, 72
S. Loibl, J. Bruey, G. Minckwitz, J. Huober, Michael Press, S. Darb-Esfahani, C. Solbach, C. Denkert, Hans Tesch, F. Holms, T. Fehm, K. Mehta, M. Untch (2011)
Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
V. Guarneri, A. Frassoldati, A. Bottini, K. Cagossi, G. Bisagni, S. Sarti, A. Ravaioli, L. Cavanna, G. Giardina, A. Musolino, M. Untch, L. Orlando, F. Artioli, C. Boni, D. Generali, P. Serra, M. Bagnalasta, L. Marini, F. Piacentini, R. D'amico, P. Conte (2012)
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 16
E. Romond, V. Suman, J. Jeong, G. Sledge, C. Geyer, S. Martino, P. Rastogi, J. Gralow, S. Swain, E. Winer, G. Colón-Otero, C. Hudis, S. Paik, N. Davidson, E. Mamounas, J. Zujewski, N. Wolmark, E. Perez, Biostatistical Centers (2012)
Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831Cancer Research, 72
F. Holmes, Y. Nagarwala, V. Espina, L. Liotta, M. Danso, Rosa Gallagher, K. McIntyre, C. Osborne, J. Mahoney, A. Florance, Thomas Anderson, J. O’Shaughnessy (2011)
Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
C. Mazouni, A. Hall, K. Broglio, H. Fritsche, F. André, F. Esteva, G. Hortobagyi, A. Buzdar, L. Pusztai, M. Cristofanilli (2007)
Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapyCancer, 109
M. Untch, P. Fasching, G. Konecny, S. Hasmüller, A. Lebeau, R. Kreienberg, O. Camara, V. Müller, A. Bois, T. Kühn, E. Stickeler, N. Harbeck, C. Höss, S. Kahlert, T. Beck, W. Fett, K. Mehta, G. Minckwitz, S. Loibl (2011)
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 25
A. Schneeweiss, S. Chia, T. Hickish, V. Harvey, A. Eniu, R. Hegg, C. Tausch, J. Seo, Y. Tsai, A. Ackrill, G. Ross, J. Cortes (2011)
S5-6: Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA).Cancer Research, 71
L. Carey, D. Berry, D. Ollila, L. Harris, I. Krop, D. Weckstein, N. Henry, C. Anders, C. Cirrincione, E. Winer, C. Perou, C. Hudis, Alliance (2013)
Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.Journal of Clinical Oncology, 31
E. Perez, A. Dueck, A. McCullough, Beiyun Chen, X. Geiger, R. Jenkins, W. Lingle, N. Davidson, S. Martino, P. Kaufman, L. Kutteh, G. Sledge, L. Harris, J. Gralow, M. Reinholz (2013)
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 17
W. Symmans, F. Peintinger, C. Hatzis, Radhika Rajan, H. Kuerer, V. Valero, L. Assad, A. Poniecka, B. Hennessy, Marjorie Green, A. Buzdar, S. Singletary, G. Hortobagyi, L. Pusztai (2007)
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 28
D. Gajria, S. Chandarlapaty (2011)
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesExpert Review of Anticancer Therapy, 11
L. Gianni, T. Pieńkowski, Y. Im, L. Roman, L. Tseng, Mei-Ching Liu, A. Lluch, E. Starosławska, J. Haba-Rodríguez, S. Im, J. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, G. Bianchi, T. Szado, J. Ratnayake, G. Ross, P. Valagussa (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.The Lancet. Oncology, 13 1
M. Rimawi, Lisa Wiechmann, Yen-chao Wang, Catherine Huang, I. Migliaccio, Meng-Fen Wu, C. Gutierrez, S. Hilsenbeck, G. Arpino, S. Massarweh, R. Ward, R. Soliz, C. Osborne, R. Schiff (2011)
Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor XenograftsClinical Cancer Research, 17
G. Minckwitz, M. Untch, J. Blohmer, S. Costa, H. Eidtmann, P. Fasching, B. Gerber, W. Eiermann, J. Hilfrich, J. Huober, C. Jackisch, M. Kaufmann, G. Konecny, C. Denkert, V. Nekljudova, K. Mehta, S. Loibl (2012)
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
D. Slamon, B. Leyland-Jones, Steven Shak, Hank Fuchs, Virginia Paton, A. Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, M. Pegram, J. Baselga, Larry Norton (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.The New England journal of medicine, 344 11
M. Scaltriti, F. Rojo, A. Ocaña, J. Anido, M. Guzman, J. Cortés, S. Cosimo, X. Matías-Guiu, S. Cajal, J. Arribas, J. Baselga (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.Journal of the National Cancer Institute, 99 8
X. Chen, X. Chen, X. Nie, C. Chen, Junlong Wu, Junlong Wu, J. Wu, Jinsong Lu, Z-M Shao, Z. Shen, K. Shen, K. Shen (2010)
Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 21 5
L. Carey, R. Metzger, E. Dees, F. Collichio, Carolyn Sartor, D. Ollila, N. Klauber-DeMore, J. Halle, L. Sawyer, D. Moore, M. Graham (2005)
American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.Journal of the National Cancer Institute, 97 15
P. Cortazar, Lijun Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, J. Zujewski, R. Justice, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, Tatiana Prowell, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, S. Swain, L. Slaets, Shenghui Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, G. Mincwitz (2012)
Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)Cancer Research, 72
R. Siegel, D. Naishadham, A. Jemal (2012)
Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 62
J. Garrett, Cammie Sutton, M. Kuba, R. Cook, C. Arteaga (2012)
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 FunctionClinical Cancer Research, 19
B. Coudert, R. Largillier, L. Arnould, P. Chollet, M. Campone, D. Coeffic, F. Priou, J. Gligorov, Xavier Martín, V. Trillet‐Lenoir, B. Weber, J. Bleuse, B. Vasseur, D. Serin, M. Namer (2007)
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 19
W. Sikov, D. Dizon, R. Strenger, R. Legare, K. Theall, T. Graves, J. Gass, T. Kennedy, M. Fenton (2009)
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
J. Baselga, J. Cortés, Sung-Bae Kim, S. Im, R. Hegg, Y. Im, L. Roman, J. Pedrini, T. Pieńkowski, A. Knott, E. Clark, M. Benyunes, G. Ross, S. Swain (2012)
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.The New England journal of medicine, 366 2
B. Dave, I. Migliaccio, M. Gutiérrez, Meng-Fen Wu, G. Chamness, H. Wong, A. Narasanna, A. Chakrabarty, S. Hilsenbeck, Jian Huang, M. Rimawi, R. Schiff, C. Arteaga, C. Osborne, Jenny Chang (2011)
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 2
L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch, S. Tjulandin, M. Zambetti, F. Vázquez, M. Byakhov, M. Lichinitser, M. Climent, E. Ciruelos, B. Ojeda, M. Mansutti, Bozhok Aa, D. Magazzù, J. Steinseifer, P. Valagussa, J. Baselga (2013)
Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.Journal of Clinical Oncology, 31
C. Hudis (2007)
Trastuzumab--mechanism of action and use in clinical practice.The New England journal of medicine, 357 1
A. Buzdar, N. Ibrahim, D. Francis, D. Booser, E. Thomas, R. Theriault, L. Pusztai, Marjorie Green, B. Arun, S. Giordano, M. Cristofanilli, D. Frye, T. Smith, K. Hunt, S. Singletary, A. Sahin, M. Ewer, T. Buchholz, D. Berry, G. Hortobagyi (2005)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 16
L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch, S. Tjulandin, M. Zambetti, F. Vázquez, Mikhail Byakhow, M. Lichinitser, M. Climent, E. Ciruelos, B. Ojeda, M. Mansutti, A. Bozhok, Roberta Baronio, A. Feyereislova, C. Barton, P. Valagussa, J. Baselga (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortThe Lancet, 375
J. Hughes, C. Berger, M. Rødland, M. Hasmann, E. Stang, I. Madshus (2009)
Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerizationMolecular Cancer Therapeutics, 8
K. Cronin, S. Plevritis, D. Fryback (2005)
Effect of screening and adjuvant therapy on mortality from breast cancerThe New England Journal of Medicine, 353
D. Mauri, N. Pavlidis, J. Ioannidis (2005)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.Journal of the National Cancer Institute, 97 3
Y. Yarden, M. Sliwkowski (2001)
Untangling the ErbB signalling networkNature Reviews Molecular Cell Biology, 2
G. Bianchini, A. Prat, M. Pickl, A. Belousov, A. Koehler, V. Semiglazov, W. Eiermann, S. Tjulandin, M. Biakhov, A. Lluch, M. Zambetti, F. Mazon, J. Baselga, L. Gianni (2011)
Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
V. Guarneri, K. Broglio, S. Kau, M. Cristofanilli, A. Buzdar, V. Valero, T. Buchholz, F. Meric, L. Middleton, G. Hortobagyi, A. González-Angulo (2006)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 7
M. Pegram, G. Konecny, C. O'Callaghan, Malgorzata Beryt, R. Pietras, D. Slamon (2004)
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.Journal of the National Cancer Institute, 96 10
V. Valero, J. Forbes, M. Pegram, T. Pieńkowski, W. Eiermann, G. Minckwitz, H. Roché, Miguel Martín, J. Crown, J. Mackey, P. Fumoleau, J. Rolski, Z. Mršić-Krmpotić, A. Jagiełło-Gruszfeld, A. Riva, M. Buyse, H. Taupin, G. Sauter, M. Press, D. Slamon (2011)
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 2
K. Blackwell, H. Burstein, A. Storniolo, H. Rugo, G. Sledge, M. Koehler, C. Ellis, M. Casey, S. Vukelja, J. Bischoff, J. Baselga, J. O’Shaughnessy (2010)
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
A. Goldhirsch, M. Piccart-Gebhart, M. Procter, E. Azambuja, H. Weber, M. Untch, I. Smith, L. Gianni, C. Jackisch, D. Cameron, R. Bell, M. Dowsett, R. Gelber, B. Leyland-Jones, J. Baselga (2012)
Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow upCancer Research, 72
M. Untch, S. Loibl, J. Bischoff, H. Eidtmann, M. Kaufmann, J. Blohmer, J. Hilfrich, D. Strumberg, P. Fasching, R. Kreienberg, H. Tesch, C. Hanusch, B. Gerber, M. Rezai, C. Jackisch, J. Huober, T. Kühn, V. Nekljudova, G. Minckwitz (2012)
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.The Lancet. Oncology, 13 2
M. Scaltriti, C. Verma, M. Guzmán, J. Jiménez, J. Parra, K. Pedersen, Derek Smith, S. Landolfi, S. Cajal, J. Arribas, J. Baselga, J. Baselga (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityOncogene, 28
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science, 235 4785
I. Witzel, S. Loibl, G. Minckwitz, H. Eidtmann, T. Fehm, F. Khandan, S. Schmatloch, M. Hauschild, Joachim Bischoff, Peter Fasching, Christine Mau, C. Schem, B. Rack, Ivo Meinhold-Heerlein, Cornelia Liedtke, T. Karn, J. Huober, C. Eulenburg, Yasmin Issa-Nummer, M. Untch, Volkmar Müller (2011)
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trialBritish Journal of Cancer, 107
J. Baselga, S. Swain (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 9
清水 千佳子 (2005)
What's going on 乳癌 Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. Mauri D, Pavlidis N, loannidis JP. J Natl Cancer Inst. 2005; 97: 188-94. PMID: 15687361--乳癌に対する術前化学療法と術後化学療法の比較:メタアナリシス, 2
H. Kuerer, L. Newman, T. Smith, F. Ames, K. Hunt, K. Dhingra, R. Theriault, Gurpreet Singh, Susan Binkley, N. Sneige, T. Buchholz, M. Ross, M. Mcneese, A. Buzdar, G. Hortobagyi, S. Singletary (1999)
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 2
Tatiana Prowell, R. Pazdur (2012)
Pathological complete response and accelerated drug approval in early breast cancer.The New England journal of medicine, 366 26
Marjorie Green, A. Buzdar, T. Smith, N. Ibrahim, V. Valero, Marguerite Rosales, M. Cristofanilli, D. Booser, L. Pusztai, E. Rivera, R. Theriault, C. Carter, D. Frye, K. Hunt, W. Symmans, E. Strom, A. Sahin, W. Sikov, G. Hortobagyi (2005)
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 25
A. Buzdar, V. Suman, F. Meric-Bernstam, A. Leitch, M. Ellis, J. Boughey, G. Unzeitig, M. Royce, K. Hunt (2013)
ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer.Journal of Clinical Oncology, 31
S. Guiu, M. Reynier, M. Toure, Bruno Coudert (2013)
Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant TherapyJournal of Oncology, 2013
A. Robidoux, G. Tang, P. Rastogi, C. Geyer, C. Azar, J. Atkins, L. Fehrenbacher, H. Bear, Luis Baez-Diaz, J. Kuebler, R. Margolese, W. Farrar, A. Brufsky, H. Shibata, H. Bandos, S. Paik, J. Costantino, S. Swain, E. Mamounas, N. Wolmark (2012)
Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 18_suppl
A. Ocaña, J. Cruz, A. Pandiella (2006)
Trastuzumab and Antiestrogen Therapy: Focus on Mechanisms of Action and ResistanceAmerican Journal of Clinical Oncology, 29
K. Ishibashi, Y. Munemoto, M. Matsuoka, T. Hata, Michiya Kobayashi, J. Hasegawa, M. Fukunaga, A. Takagane, T. Otsuji, Y. Miyake, M. Nagase, K. Oba, J. Sakamoto, H. Mishima (2013)
XELOX with bevacizumab in elderly patients age 75 or older with metastatic colorectal cancer: Results of a planned interim analysis for multicenter phase II ASCA study.Journal of Clinical Oncology, 31
F. Holmes, V. Espina, L. Liotta, J. Chang, Y. Nagarwala, M. Danso, K. McIntyre, C. Osborne, L. Krekow, R. Gagnon, J. Mahoney, J. O’Shaughnessy (2011)
P5-13-03: Correlation of Clinical and Molecular Findings with Pathologic Response to Preoperative Lapatinib and Trastuzumab, Separately or in Combination, Prior to Neoadjuvant Chemotherapy for HER2 Positive Breast Cancer.Cancer Research, 71
R. Rouzier, C. Perou, W. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson, K. Hess, J. Stec, J. Stec, M. Ayers, P. Wagner, P. Morandi, Chang Fan, Islam Rabiul, J. Ross, G. Hortobagyi, L. Pusztai (2005)
Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 11
P. Rastogi, S. Anderson, H. Bear, C. Geyer, M. Kahlenberg, A. Robidoux, R. Margolese, J. Hoehn, V. Vogel, S. Dakhil, D. Tamkus, K. King, E. Pajon, Mary Wright, J. Robert, S. Paik, E. Mamounas, N. Wolmark (2008)
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 5
G. Minckwitz, M. Rezai, S. Loibl, P. Fasching, J. Huober, H. Tesch, I. Bauerfeind, J. Hilfrich, H. Eidtmann, B. Gerber, C. Hanusch, T. Kühn, A. Bois, J. Blohmer, C. Thomssen, S. Costa, C. Jackisch, M. Kaufmann, K. Mehta, M. Untch (2010)
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 12
G. Minckwitz, A. Schneeweiss, C. Salat, M. Rezai, D. Zahm, P. Klare, J.-U. Blohmer, H. Tesch, F. Khandan, S. Jud, C. Jackisch, K. Mehta, S. Loibl, M. Untch (2013)
A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto).Journal of Clinical Oncology, 31
M. Untch, M. Rezai, S. Loibl, P. Fasching, J. Huober, H. Tesch, I. Bauerfeind, J. Hilfrich, H. Eidtmann, B. Gerber, C. Hanusch, T. Kühn, A. Bois, J. Blohmer, C. Thomssen, S. Costa, C. Jackisch, M. Kaufmann, K. Mehta, G. Minckwitz (2010)
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 12
Mdii Osborne, G. Arpino, C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, L. Bharwani, S. Placido, R. Schiff (2007)
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.Journal of the National Cancer Institute, 99 9
The neoadjuvant strategy, initially developed to render primary inoperable tumors operable, is now increasingly being utilized for patients with triple-negative and HER2 positive breast cancer in clinical trials in order to assess for response and resistance with the incorporation of tissue biopsy studies. Pathological complete response (pCR) has been accepted as a primary endpoint in a number of neoadjuvant trials for operable HER2+ disease. This article provides a comprehensive summary of the knowledge gained from neoadjuvant trials conducted with HER2 directed agents to date, focuses on the concept of dual blockade of HER2, highlights the importance of predictive biomarkers, and finally puts them into perspective with current treatment recommendations and future research and trends.
Current Breast Cancer Reports – Springer Journals
Published: Nov 15, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.